Decision and Details
Board of DirectorsExecution of a design and construction contract for Okayama No. 2 Plant
Further strengthening of the BCP (business continuity plan) and improvement of production efficiency, expansion of the supply capacity for powdered dialysis agents, reorganization and consolidation of the domestic production facility network, and improvement of manufacturing efficiency
There is no change to the earnings forecast for the fiscal year ending March 2027
| Item | Details |
|---|---|
| Matter Covered | Execution of a design and construction contract for Okayama No. 2 Plant |
| Decision-Making Body | Board of Directors |
| Decision Date | 30 September 2026 |
| Implementation Date | Contract executed on 30 September 2026 (completed); construction scheduled to start in December 2026; completion scheduled for March 2028; manufacturing scheduled to begin in December 2028 |
| Amount | Total investment: approximately ¥14 billion (including buildings, production equipment and related costs) |
| Quantity / scale | Building area: approximately 3,400 m²; total floor area: approximately 8,800 m²; five-story steel-frame structure; automated high-bay warehouse to be included |
| Impact on Business Performance | There is no change to the earnings forecast for the fiscal year ending March 2027 |
| Reason | Further strengthening of the BCP (business continuity plan) and improvement of production efficiency, expansion of the supply capacity for powdered dialysis agents, reorganization and consolidation of the domestic production facility network, and improvement of manufacturing efficiency |
| Related previous disclosures | Medium-Term Management Policy "FUSO Vision 2030 Next Stage," announced on 8 August 2025; "Summary of Financial Results for the Fiscal Year Ended March 2026 [Japanese GAAP] (Non-consolidated)," announced on 12 May 2026 |
| Future plans | Construction scheduled to start in December 2026, completion scheduled for March 2028, and manufacturing scheduled to begin in December 2028 |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The objectives are to strengthen the BCP (business continuity plan), improve production efficiency, expand the supply capacity for powdered dialysis agents, reorganize and consolidate the domestic production facility network, and improve manufacturing efficiency.